
The Sofinnova Capital XI fund round was supported by a global mix of institutional investors, including sovereign wealth funds, leading pharmaceutical companies and corporates, insurance companies, foundations, and family offices from Europe, North America, Asia, and the Middle East.

The investment was backed by KBC Focus Fund, Cap Horn, Bpifrance, the European Innovation Council Fund, Elaia Partners, Sensinnovat and Beeyond.

Dialog’s $4.4 million seed round was led by Galion.exe.